Zymeworks

Index
Globenewswire

Ziihera® (zanidatamab-hrii) Combinations Achieve Unprecedented Results in First-Line HER2+ Locally Advanced or Metastatic GEA including more than Two Years Median Overall Survival Benefit

Globenewswire

Zymeworks Appoints Scott Platshon as Acting Chief Investment Officer

Globenewswire

Zymeworks Announces Strategic Initiative to Optimize Value of Licensed Products by Building a Diversified Portfolio of Revenue-Generating Assets

Globenewswire

Zymeworks Announces Positive HERIZON-GEA-01 Phase 3 Results Supporting Ziihera® (zanidatamab-hrii) as HER2-Targeted Agent-of-Choice and New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma

Globenewswire

Zymeworks Presents Initial Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺ at AACR-NCI-EORTC Conference

Globenewswire

Zymeworks to Present Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺, at AACR-NCI-EORTC International Conference

Globenewswire

Zymeworks Appoints Dr. Adam Schayowitz as Acting Chief Development Officer

Globenewswire

Zymeworks Announces Decision to Discontinue Clinical Development of ZW171, a Mesothelin-directed T cell Engager

Globenewswire

Zymeworks Strengthens Board of Directors with Appointments of Greg Ciongoli and Robert E. Landry

Globenewswire

Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW251, a Novel Glypican 3-Targeted Topoisomerase 1 Inhibitor Antibody-Drug Conjugate

Globenewswire

Zymeworks to Report Second Quarter 2025 Financial Results and Host Conference Call on August 7, 2025

Globenewswire

Zymeworks Announces NMPA Approval of Zanidatamab in China for Adults with Previously Treated, Unresectable or Metastatic HER2-high expression (IHC3+) Biliary Tract Cancer

Globenewswire

Zymeworks Announces Presentations Highlighting Breadth of Oncology Portfolio at Upcoming Medical Conferences

Globenewswire

Zymeworks Announces Participation in Upcoming Investor Conferences-.

Globenewswire

Zymeworks Presents Preclinical Data on ZW1528 at the American Thoracic Society International Conference

Globenewswire

Zymeworks Presents New Data from Multiple Development Programs at 2025 AACR Annual Meeting

Globenewswire

Zymeworks Appoints Dr. Sabeen Mekan as Senior Vice President, Clinical Development

Globenewswire

Zymeworks Announces Participation in Upcoming Investor Conferences (March 26, 2025)

Globenewswire

Zymeworks to Present Preclinical Data on T cell Engager and Antibody-Drug Conjugate Platforms in Six Posters at AACR Annual Meeting

Globenewswire

Zymeworks Announces Achievement of $14 Million Milestone from GSK Collaboration

Globenewswire

Zymeworks To Report Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 5, 2025

Globenewswire

Zymeworks Outlines Strategic Priorities and Outlook for 2025 and 2026

Globenewswire

Zymeworks Hosts R&D Day Highlighting Continued Clinical Progress in Oncology Programs and Expansion into Autoimmune and Inflammatory Diseases

Globenewswire

Zymeworks Announces Participation in Upcoming Investor Conferences-

Globenewswire

FDA Grants U.S. Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC)